Back to Market返回行情

DVA DaVita Inc.

USHealthcare
$232.80+1.45%ClosedMarket Cap: $14.94B

As of 2026-07-10 16:00

Why DVA matters now

DaVita Inc. (DVA) is a US stock in Healthcare. The latest InvestLog snapshot shows $232.80 with +1.45% on the session and $14.94B in market capitalization; recent performance reads 1-month +6.83% and YTD +83.00%.

The latest financial table shown here is Q1 2026, with revenue of $3.42B, net income of $197.5M, and EPS of $2.87. Investors can compare that operating picture with valuation signals such as P/E 13.43 and FCF yield 11.2%.

The latest indexable market news headline is "DaVita HealthCare (DVA) Laps the Stock Market: Here's Why" from Zacks Investment Research.

Additional event context on this page matters because analyst consensus is Hold with a median target of $199.50; recent insider activity includes Rodriguez Javier filing S-Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

13.43

PEG

P/B

-18.55

P/S

0.96

EV/EBITDA

9.57

DCF Value

$232.40

FCF Yield

11.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

31.1%

Operating Margin

15.0%

Net Margin

5.6%

ROE

-133.1%

ROA

4.5%

ROIC

10.7%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$3.42B$197.5M$2.87
Q4 2025$3.62B$234.2M$2.45
FY 2025$13.64B$746.8M$9.51
Q3 2025$3.42B$150.3M$2.04

Analyst Ratings

Consensus

Hold

Target (Consensus)

$202.25

Target (Median)

$199.50

Target Range

$190.00 - $220.00

Strong Buy: 0Buy: 2Hold: 4Sell: 0Strong Sell: 2
TD CowenHold
2026-05-11
BarclaysEqual Weight
2026-05-08
Truist SecuritiesHold
2026-05-08
UBSBuy
2026-05-07
Deutsche BankBuy
2026-05-06

Trading Activity

Insider Trades

Rodriguez Javierdirector, officer: Chief Executive Officer
Sell2026-06-17
Rodriguez Javierdirector, officer: Chief Executive Officer
Sell2026-06-17
Waters Kathleen Alyceofficer: Chief Legal & Pub. Affairs Off
Sell2026-06-17
Waters Kathleen Alyceofficer: Chief Legal & Pub. Affairs Off
Sell2026-06-17
YALE PHYLLIS Rdirector
Sell2026-05-28

Company Info

Sector

Healthcare

Industry

Medical - Care Facilities

Country

US

Exchange

Beta

0.91

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.